Literature DB >> 2591434

Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action.

S Hill1, K B Williams, J Denekamp.   

Abstract

Flavone acetic acid (FAA, LM 975) causes regression and growth retardation in several solid murine tumours. The mechanism of action is unknown, although various lines of evidence suggest an indirect cytotoxic effect. We have carried out preliminary studies on the effect of FAA on relative blood flow in six experimental murine tumours using 86RbCl extraction. We have also measured growth delay after treatment with the same dose of FAA (200 mg/kg). The data show that the drug induces a drop in tumour perfusion within 6 h of treatment in all of the tumours, and that this can be correlated with the growth delay measured. We conclude that vascular collapse may be an important component of the action of this drug, and that further investigation of this phenomenon is warranted.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2591434     DOI: 10.1016/0277-5379(89)90099-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  24 in total

1.  Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA.

Authors:  M E Watts; S Arnold; D J Chaplin
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice.

Authors:  Minh Hien Pham; Hervé Rhinn; Nicolas Auzeil; Anne Regazzetti; Djamel Eddine Harami; Daniel Scherman; Guy G Chabot
Journal:  Drug Metab Lett       Date:  2011-04

3.  The ultra-performance liquid chromatography tandem mass spectrometry method for detection and quantification of C4NP in rat plasma and its application to pharmacokinetic studies.

Authors:  J You; L Wang; F Yang; J Shang
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

4.  The comparative disposition of the pyrolloquinone GR63178A and its 9-hydroxy metabolite GR54374X in sensitive and resistant mouse colon adenocarcinoma.

Authors:  R C French; J Cummings; A MacLellan; J S MacPherson; A A Ritchie; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Vascular attack as a therapeutic strategy for cancer.

Authors:  J Denekamp
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

6.  Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization.

Authors:  Yasmine S Touil; Arlette Fellous; Daniel Scherman; Guy G Chabot
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

Review 7.  The biology of the combretastatins as tumour vascular targeting agents.

Authors:  Gillian M Tozer; Chryso Kanthou; Charles S Parkins; Sally A Hill
Journal:  Int J Exp Pathol       Date:  2002-02       Impact factor: 1.925

8.  Cyclosporine is angiostatic.

Authors:  K Norrby
Journal:  Experientia       Date:  1992-12-01

9.  5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.

Authors:  G J S Rustin; C Bradley; S Galbraith; M Stratford; P Loadman; S Waller; K Bellenger; L Gumbrell; L Folkes; G Halbert
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

10.  A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.

Authors:  K Hori; S Saito; K Kubota
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.